Clinical-stage immune-oncology company CARsgen Therapeutics revealed on Wednesday that its BCMA CAR-T cell has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).
This IND clearance for the company's drug candidate, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell, relates to the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM).
CT053 has received IND clearance from the National Medical Products Administration in China four months ago and is the subject of an ongoing phase I clinical trial.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell.
At the 5th Annual Immunotherapy in Myeloma Scientific Workshop in Denver, Colorado, the company provided an update of the clinical data of CT053 showing that 87.5% of the patients showed overall response to the treatment. 70.8% of the patients had complete response and no grade three or higher cytokine release syndrome (CRS) was observed in 24 heavily pre-treated patients with rrMM. The IND clearance of CT053 by the FDA is of great significance to patients, said its founder Dr Zonghai Li.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial